MedTrace Logo

Evaluation of Effectiveness of Two Different Doses of Mivacurium in Rapid Sequence Intubation

NCT06072534 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-01-30

No results posted yet for this study

Summary

Mivacurium can be considered as an optimal choice for muscle relaxation in short duration surgeries, as butyrylcholinesterase can rapidly and reliably degrade this benzylisoquinoline muscle relaxant in vivo. However the histamine release related to a rapid high-dose injection, unsatisfactory intubation conditions and unexpected delay in recovery in patients may be encountered with butyrylcholinesterase deficiency

Conditions

  • Emergencies

Interventions

DRUG

"Mivacurium Chloride"

emergence modified sequence intubation

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • ismail m ahmed, professor · Al-Azhar University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06072534 on ClinicalTrials.gov